

Irene Litvan,, Faan, Fana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4064285/publications.pdf>

Version: 2024-02-01

393
papers

57,352
citations

2318

98
h-index

1187

228
g-index

409
all docs

409
docs citations

409
times ranked

32940
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in Self- and Informant-Reported Frontal Behaviors in Parkinsonâ€™s Disease: A Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 89-101.	1.2	2
2	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. <i>Brain</i> , 2022, 145, 1079-1097.	3.7	30
3	Association of Stress-Health Factors among Parkinsonâ€™s Disease Patient/Caregiving-Partner Dyads. <i>Archives of Clinical Neuropsychology</i> , 2022, 37, 12-18.	0.3	2
4	Current directions in tau research: Highlights from Tau 2020. <i>Alzheimer's and Dementia</i> , 2022, 18, 988-1007.	0.4	42
5	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. <i>Alzheimer's and Dementia</i> , 2022, 18, 1635-1649.	0.4	9
6	Wearable electrochemical microneedle sensing platform for real-time continuous interstitial fluid monitoring of apomorphine: Toward Parkinson management. <i>Sensors and Actuators B: Chemical</i> , 2022, 354, 131234.	4.0	32
7	<scp>Physicianâ€™Assisted</scp> Dying: Access and Utilization in Patients with Movement Disorders. <i>Movement Disorders</i> , 2022, 37, 694-698.	2.2	2
8	Transcriptional analysis of peripheral memory T cells reveals Parkinsonâ€™s disease-specific gene signatures. <i>Npj Parkinson's Disease</i> , 2022, 8, 30.	2.5	20
9	Internetwork Connectivity Predicts Cognitive Decline in Parkinsonâ€™s and Is Altered by Genetic Variants. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 853029.	1.7	4
10	Level I <scp>PDâ€™MCI</scp> Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483.	0.8	11
11	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. <i>Movement Disorders</i> , 2022, 37, 1265-1271.	2.2	9
12	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	2.2	222
13	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTLD spectrum disorders. <i>Cell Reports Medicine</i> , 2022, 3, 100607.	3.3	21
14	Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology. <i>Movement Disorders</i> , 2022, 37, 1505-1515.	2.2	12
15	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200582.	1.5	0
16	A Pilot Randomized Controlled Trial Investigating MBSR for Parkinsonâ€™s Disease Patients and Their Caregiving Partners: Effects on Distress, Social support, Cortisol, and Inflammation. <i>Mindfulness</i> , 2022, 13, 1271-1280.	1.6	0
17	Investigational therapeutics for the treatment of progressive supranuclear palsy. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 813-823.	1.9	1
18	Differential impact of individual autonomic domains on clinical outcomes in Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2022, 269, 5510-5520.	1.8	9

#	ARTICLE	IF	CITATIONS
19	Closing the loop for patients with Parkinson disease: where are we?. <i>Nature Reviews Neurology</i> , 2022, 18, 497-507.	4.9	19
20	Differences in Motor Features of <i>C9orf72</i> , <i>MAPT</i> , or <i>GRN</i> Variant Carriers With Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2022, 99, .	1.5	5
21	Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinson's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2021, 28, 812-828.	0.7	3
22	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	1.7	21
23	Delineation of Apathy Subgroups in Parkinson's Disease: Differences in Clinical Presentation, Functional Ability, Health-related Quality of Life, and Caregiver Burden. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 92-99.	0.8	6
24	Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 151-176.	0.8	10
25	Medication Management Performance in Parkinson's Disease: Examination of Process Errors. <i>Archives of Clinical Neuropsychology</i> , 2021, 36, 1307-1315.	0.3	4
26	The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 210-219.	0.9	111
27	Sex differences for phenotype in pathologically defined dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 745-750.	0.9	23
28	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 115-122.	1.1	10
29	Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 182-192.	4.9	74
30	Assessment of Motor Dysfunction with Virtual Reality in Patients Undergoing [123I]FP-CIT SPECT/CT Brain Imaging. <i>Tomography</i> , 2021, 7, 95-106.	0.8	2
31	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. <i>Npj Parkinson's Disease</i> , 2021, 7, 16.	2.5	10
32	Career Development Program for Underrepresented in Medicine Scholars in Academic Neurology. <i>Neurology</i> , 2021, 97, 125-133.	1.5	7
33	Worldwide barriers to genetic testing for movement disorders. <i>European Journal of Neurology</i> , 2021, 28, 1901-1909.	1.7	21
34	Gene-Environment Interactions in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2021, 12, 664796.	1.1	1
35	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.5	52
36	Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. <i>Frontiers in Neurology</i> , 2021, 12, 648532.	1.1	21

#	ARTICLE	IF	CITATIONS
37	Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behavioral Sciences (Basel, Switzerland), 2021, 11, 74.	1.0	39
38	Environmental Risk Factors for Progressive Supranuclear Palsy. Journal of Movement Disorders, 2021, 14, 103-113.	0.7	8
39	Hispanic Perspectives on Parkinson's Disease Care and Research Participation. Journal of Alzheimer's Disease, 2021, 81, 809-819.	1.2	11
40	A Microstirring Pill Enhances Bioavailability of Orally Administered Drugs. Advanced Science, 2021, 8, 2100389.	5.6	23
41	Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database. Frontiers in Neurology, 2021, 12, 571800.	1.1	14
42	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	1.1	12
43	Association of Orthostatic Hypotension With Cerebral Atrophy in Patients With Lewy Body Disorders. Neurology, 2021, 97, e814-e824.	1.5	14
44	Non-Invasive Sweat-Based Tracking of L-Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. Angewandte Chemie - International Edition, 2021, 60, 19074-19078.	7.2	36
45	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. Frontiers in Neurology, 2021, 12, 694872.	1.1	29
46	Non-Invasive Sweat-Based Tracking of L-Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. Angewandte Chemie, 2021, 133, 19222-19226.	1.6	10
47	Reply to: "Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?" Movement Disorders, 2021, 36, 1999-2000.	2.2	0
48	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 2021, 27, 1451-1457.	15.2	63
49	Semantic Recollection in Parkinson's Disease: Functional Reconfiguration and MAPT Variants. Frontiers in Aging Neuroscience, 2021, 13, 727057.	1.7	4
50	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression. JAMA - Journal of the American Medical Association, 2021, 326, 926.	3.8	80
51	Informant-Reported Cognitive Decline is Associated with Objective Cognitive Performance in Parkinson's Disease. Journal of the International Neuropsychological Society, 2021, 27, 439-449.	1.2	3
52	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
53	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH's EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
54	4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathologica, 2020, 139, 63-77.	3.9	89

#	ARTICLE	IF	CITATIONS
55	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
56	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 37-48.	0.4	38
57	Abnormal distraction and loadâ€specific connectivity during working memory in cognitively normal Parkinson's disease. <i>Human Brain Mapping</i> , 2020, 41, 1195-1211.	1.9	14
58	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, 49-59.	0.4	27
59	Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. <i>Neurology</i> , 2020, 94, e774-e784.	1.5	24
60	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 121-126.	1.1	11
61	Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 56-60.	1.1	9
62	Parkinson disease with mild cognitive impairment: Domainâ€specific cognitive complaints predict dementia. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 585-596.	1.0	9
63	Lowering the risk of Parkinsonâ€™s disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes. <i>Brain</i> , 2020, 143, 2868-2871.	3.7	7
64	Orthostatic hypotension preceding dementia with Lewy bodies by over 15Âyears: a clinicopathologic case report. <i>Clinical Autonomic Research</i> , 2020, 30, 575-577.	1.4	3
65	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 127-132.	1.1	10
66	Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 961-964.	0.8	3
67	Orthostatic Hypotension Is Associated With Cognitive Decline in Parkinson Disease. <i>Frontiers in Neurology</i> , 2020, 11, 897.	1.1	18
68	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <sc>Movement Disorder Society</sc> Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	0.8	31
69	The complexity of DLB: U.S.â€based Dementia with Lewy Body Consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, e042846.	0.4	0
70	Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol. <i>Alzheimer's and Dementia</i> , 2020, 16, e045482.	0.4	0
71	Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD). <i>Alzheimer's and Dementia</i> , 2020, 16, e046247.	0.4	0
72	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. <i>Neurology</i> , 2020, 95, e35-e45.	1.5	9

#	ARTICLE	IF	CITATIONS
73	Pathologyâ€Proven Corticobasal Degeneration Presenting as Richardson's Syndrome. Movement Disorders Clinical Practice, 2020, 7, 267-272.	0.8	6
74	Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases. Alzheimer's and Dementia, 2020, 16, 118-130.	0.4	43
75	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	2.2	31
76	Utility of the global CDR^{Â®} plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 2020, 16, 106-117.	0.4	81
77	Progressive Supranuclear Palsy and Statin Use. Movement Disorders, 2020, 35, 1253-1257.	2.2	2
78	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. Annals of Clinical and Translational Neurology, 2020, 7, 449-461.	1.7	44
79	Î±-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinsonâ€™s disease. Nature Communications, 2020, 11, 1875.	5.8	239
80	Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism and Related Disorders, 2020, 73, 105-116.	1.1	55
81	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
82	Resting state functional connectivity in levodopa non responsive Parkinson's disease patients with freezing of gait. Parkinsonism and Related Disorders, 2020, 79, e8.	1.1	0
83	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. Alzheimer's and Dementia, 2019, 15, 1218-1228.	0.4	34
84	Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management. ACS Sensors, 2019, 4, 2196-2204.	4.0	196
85	Hypertension and progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 166-170.	1.1	12
86	Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinsonâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2019, 47, 187-197.	0.7	15
87	Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. Parkinsonism and Related Disorders, 2019, 66, 87-93.	1.1	21
88	Occupation and Parkinson disease in the Women's Health Initiative Observational Study. American Journal of Industrial Medicine, 2019, 62, 766-776.	1.0	9
89	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. Parkinsonism and Related Disorders, 2019, 69, 34-39.	1.1	18
90	B-18 Executive Functioning Best Predicts Performance-Based Financial Skills in Non-Demented Parkinsonâ€™s Disease. Archives of Clinical Neuropsychology, 2019, 34, 963-963.	0.3	1

#	ARTICLE	IF	CITATIONS
91	Frontrunner in Translation: Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2019, 10, 1125.	1.1	19
92	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1655-1662.	2.2	14
93	End of life planning in parkinsonian diseases. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 73-78.	1.1	8
94	Treatment of Progressive Supranuclear Palsy. <i>Current Clinical Neurology</i> , 2019, , 137-140.	0.1	1
95	The role of dispositional mindfulness in a stress-health pathway among Parkinson's disease patients and caregiving partners. <i>Quality of Life Research</i> , 2019, 28, 2705-2716.	1.5	11
96	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. <i>Lancet Neurology</i> , The, 2019, 18, 549-558.	4.9	108
97	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 23.	3.0	9
98	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	2.2	93
99	Factor Analysis of the Apathy Scale in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 379-386.	0.8	13
100	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.5	194
101	Nonlinear Z-score modeling for improved detection of cognitive abnormality. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 797-808.	1.2	12
102	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.	1.1	7
103	The virtual reality of Parkinson's disease freezing of gait: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 26-33.	1.1	22
104	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , 2019, 34, 430-435.	2.2	32
105	Progress in the treatment of Parkinson-Plus syndromes. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 101-110.	1.1	6
106	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. <i>Movement Disorders</i> , 2018, 33, 468-472.	2.2	14
107	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 503-510.	2.2	52
108	Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 520-527.	2.2	14

#	ARTICLE	IF	CITATIONS
109	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 501-502.	2.2	1
110	Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 349-361.	1.9	20
111	Anti-inflammatory drug use and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 89-92.	1.1	6
112	Prominent Tongue and Jaw Tremor in a Patient with Probable Progressive Supranuclear Palsy. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 99-100.	0.8	4
113	P1433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC <i>L</i> MAPT MUTATION CARRIERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P475.	0.4	0
114	Altered Functional Interactions of Inhibition Regions in Cognitively Normal Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 331.	1.7	10
115	Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1539-1548.	1.2	11
116	Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. <i>Neurology</i> , 2018, 91, 797-799.	1.5	34
117	Does the Geriatric Depression Scale measure depression in Parkinson's disease?. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1662-1670.	1.3	15
118	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	2.2	42
119	Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans. <i>Frontiers in Neurology</i> , 2018, 9, 474.	1.1	22
120	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	2.2	114
121	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	2.2	171
122	Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. <i>Neurodegenerative Diseases</i> , 2018, 18, 173-190.	0.8	18
123	Tauopathy-Associated PERK Alleles are Functional Hypomorphs that Increase Neuronal Vulnerability to ER Stress. <i>Human Molecular Genetics</i> , 2018, 27, 3951-3963.	1.4	36
124	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	1.1	33
125	Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 387-394.	1.8	9
126	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. <i>Acta Neuropathologica</i> , 2018, 136, 389-404.	3.9	59

#	ARTICLE	IF	CITATIONS
127	Psychometric Properties and Characteristics of the Northâ€East Visual Hallucinations Interview in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 717-723.	0.8	13
128	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
129	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. <i>Movement Disorders</i> , 2017, 32, 955-971.	2.2	179
130	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	2.2	1,402
131	Therapeutic options for Progressive Supranuclear Palsy including investigational drugs. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 575-587.	0.5	5
132	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017, 32, 1056-1065.	2.2	117
133	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2017, 16, 552-563.	4.9	303
134	Levodopaâ€Responsive Parkinsonism Associated with Giant Virchowâ€Robin Spaces: A Case Report. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 619-622.	0.8	3
135	Understanding falls in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 75-81.	1.1	15
136	Genetic influences on cognition in progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 1764-1771.	2.2	6
137	¹⁸ Fâ€flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. <i>Annals of Neurology</i> , 2017, 82, 622-634.	2.8	148
138	Neuropsychiatric Predictors of Cognitive Decline in Parkinson Disease: A Longitudinal Study. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 279-289.	0.6	38
139	[O2â€17â€01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBOâ€CONTROLLED STUDY OF ABBVâ€E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P599.	0.4	9
140	The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy. <i>Journal of Parkinson's Disease</i> , 2017, 7, 377-383.	1.5	4
141	Fall Prediction and Prevention Systems: Recent Trends, Challenges, and Future Research Directions. <i>Sensors</i> , 2017, 17, 2509.	2.1	107
142	Aberrant Intrinsic Activity and Connectivity in Cognitively Normal Parkinsonâ€TM's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 197.	1.7	27
143	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	1.1	110
144	Environmental Exposures and Parkinsonâ€TM's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 881.	1.2	151

#	ARTICLE	IF	CITATIONS
145	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. PLoS ONE, 2016, 11, e0157218.	1.1	40
146	Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders, 2016, 31, 1272-1282.	2.2	464
147	Î±â€šynuclein genetic variability: A biomarker for dementia in Parkinson disease. Annals of Neurology, 2016, 79, 991-999.	2.8	85
148	Environmental and occupational risk factors for progressive supranuclear palsy: Caseâ€šcontrol study. Movement Disorders, 2016, 31, 644-652.	2.2	53
149	Relationship between uric acid levels and progressive supranuclear palsy. Movement Disorders, 2016, 31, 663-667.	2.2	11
150	Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. Cogent Psychology, 2016, 3, 1131476.	0.6	14
151	The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548.	4.9	82
152	Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease. Parkinsonism and Related Disorders, 2016, 27, 54-60.	1.1	23
153	Abolishing the 1â€šyear rule: How much evidence will be enough?. Movement Disorders, 2016, 31, 1623-1627.	2.2	43
154	Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis. Movement Disorders Clinical Practice, 2016, 3, 65-67.	0.8	6
155	Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology, 2016, 87, 2016-2025.	1.5	65
156	Cognitive functioning in individuals with Parkinsonâ€™s disease and traumatic brain injury: A longitudinal study. Parkinsonism and Related Disorders, 2016, 30, 58-61.	1.1	7
157	The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathologica, 2016, 131, 75-86.	3.9	708
158	Progressive supranuclear palsy: progression and survival. Journal of Neurology, 2016, 263, 380-389.	1.8	55
159	Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers). Quality of Life Research, 2016, 25, 81-88.	1.5	20
160	Head injury exposure in PSP: a case-control study. Journal of the Neurological Sciences, 2015, 357, e275.	0.3	0
161	MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2015, 30, 1600-1611.	2.2	1,033
162	The RAB39B p.G192R mutation causes X-linked dominant Parkinsonâ€™s disease. Molecular Neurodegeneration, 2015, 10, 50.	4.4	91

#	ARTICLE	IF	CITATIONS
163	Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. <i>Journal of Parkinson's Disease</i> , 2015, 5, 971-981.	1.5	15
164	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 127-134.	0.8	20
165	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	2.2	4,389
166	Swallowing disturbances in the corticobasal syndrome. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1342-1348.	1.1	9
167	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. <i>Nature Communications</i> , 2015, 6, 7247.	5.8	170
168	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e7-1605.e12.	1.5	96
169	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 919-927.	2.2	244
170	Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 253-265.	0.5	6
171	The Wearable Multimodal Monitoring System: A Platform to Study Falls and Near-Falls in the Real-World. <i>Lecture Notes in Computer Science</i> , 2015, , 412-422.	1.0	5
172	Corticobasal Degeneration. <i>Seminars in Neurology</i> , 2014, 34, 160-173.	0.5	47
173	Dissociation of Neural Mechanisms for Intersensory Timing Deficits in Parkinson's Disease. <i>Timing and Time Perception</i> , 2014, 2, 145-168.	0.4	19
174	Rate of decline in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014, 29, 463-468.	2.2	30
175	Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 360-367.	2.2	55
176	Cognition in movement disorders: Where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014, 29, 704-711.	2.2	15
177	Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO). <i>Pharmacotherapy</i> , 2014, 34, 1250-1258.	1.2	42
178	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	4.5	312
179	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. <i>Movement Disorders</i> , 2014, 29, 470-478.	2.2	251
180	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. <i>Nature Genetics</i> , 2014, 46, 989-993.	9.4	1,685

#	ARTICLE	IF	CITATIONS
181	A disposable electrochemical biosensor for L-DOPA determination in undiluted human serum. <i>Electrochemistry Communications</i> , 2014, 48, 28-31.	2.3	29
182	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	2.2	379
183	Correcting for Demographic Variables on the Modified Telephone Interview for Cognitive Status. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1438-1443.	0.6	8
184	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	4.9	245
185	The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 627-631.	1.1	37
186	Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 503-507.	1.1	34
187	Pan-American Consortium of Multiple System Atrophy (PANMSA). A Pan-American multicentre cohort study of Multiple System Atrophy. <i>Journal of Parkinson's Disease</i> , 2014, 4, 693-698.	1.5	10
188	Instrumental activities of daily living are impaired in Parkinson's disease patients with mild cognitive impairment.. <i>Neuropsychology</i> , 2014, 28, 229-237.	1.0	75
189	Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. <i>Journal of Parkinson's Disease</i> , 2014, 4, 131-137.	1.5	50
190	The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 31.	2.4	148
191	The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 463-465.	1.1	1
192	Long-duration Parkinson's disease: Role of lateralization of motor features. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 77-80.	1.1	34
193	Behavioral abnormalities in progressive supranuclear palsy. <i>Psychiatry Research</i> , 2013, 210, 1205-1210.	1.7	113
194	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013, 80, 496-503.	1.5	1,445
195	Measuring mild cognitive impairment in patients with Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 626-633.	2.2	120
196	White-Matter Changes Correlate with Cognitive Functioning in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2013, 4, 37.	1.1	53
197	Executive Dysfunction Is the Primary Cognitive Impairment in Progressive Supranuclear Palsy. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 104-113.	0.3	79
198	Parkinsonian Syndromes. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 1189-1212.	0.4	65

#	ARTICLE	IF	CITATIONS
199	Functional impairment in progressive supranuclear palsy. <i>Neurology</i> , 2013, 80, 380-384.	1.5	13
200	Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 67-75.	0.7	47
201	Predictors of performance-based measures of instrumental activities of daily living in nondemented patients with Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 926-933.	0.8	28
202	Primary Health Care Providers' Knowledge Gaps on Parkinson's Disease. <i>Educational Gerontology</i> , 2013, 39, 856-862.	0.7	7
203	Neuropsychiatric and cognitive disorders in other parkinsonian disorders. , 2013, , 261-274.		3
204	Phosphorylated α -Synuclein in Parkinson's Disease. <i>Science Translational Medicine</i> , 2012, 4, 121ra20.	5.8	223
205	Roles of Education and IQ in Cognitive Reserve in Parkinson's Disease-Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 343-352.	0.6	36
206	Reply: Mild cognitive impairment in de novo Parkinson's disease according to Movement Disorder guidelines. <i>Movement Disorders</i> , 2012, 27, 1707-1707.	2.2	2
207	Toward magnetic resonance imaging biomarkers for progressive supranuclear palsy and multisystem atrophy. <i>Movement Disorders</i> , 2012, 27, 1711-1713.	2.2	3
208	Brain-Lung-Thyroid Disease. <i>Journal of Child Neurology</i> , 2012, 27, 68-73.	0.7	12
209	Annonacin in <i>Asimina triloba</i> fruit: Implication for neurotoxicity. <i>NeuroToxicology</i> , 2012, 33, 53-58.	1.4	46
210	Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study. <i>BMC Medical Genetics</i> , 2012, 13, 16.	2.1	3
211	The pill questionnaire in a nondemented Parkinson's disease population. <i>Movement Disorders</i> , 2012, 27, 1308-1311.	2.2	15
212	Meta-analysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i> . <i>Annals of Neurology</i> , 2012, 71, 370-384.	2.8	264
213	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	2.2	1,908
214	Examining the motor phenotype of patients with both essential tremor and Parkinson's disease. <i>Tremor and Other Hyperkinetic Movements</i> , 2012, 2, .	1.1	10
215	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011, 43, 699-705.	9.4	502
216	Cytokine expression and microglial activation in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 683-688.	1.1	64

#	ARTICLE	IF	CITATIONS
217	Assessment of cognition in early dementia. <i>Alzheimer's and Dementia</i> , 2011, 7, e60-e76.	0.4	75
218	Measuring quality of life in progressive supranuclear palsy. , 2011, , 52-59.		1
219	Parkinsonism and Frontotemporal Dementia: The Clinical Overlap. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 343-349.	1.1	48
220	Milestones in atypical and secondary Parkinsonisms. <i>Movement Disorders</i> , 2011, 26, 1083-1095.	2.2	74
221	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PDâ€MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824.	2.2	649
222	Rapidly progressive atypical parkinsonism associated with frontotemporal lobar degeneration and motor neuron disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 751-753.	0.9	15
223	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. <i>Brain</i> , 2011, 134, 3264-3275.	3.7	119
224	Copy Number Variation in Familial Parkinson Disease. <i>PLoS ONE</i> , 2011, 6, e20988.	1.1	67
225	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1077-1081.	2.2	106
226	H1/H1 genotype influences symptom severity in corticobasal syndrome. <i>Movement Disorders</i> , 2010, 25, 760-763.	2.2	6
227	A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2501-2507.	2.2	155
228	A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 423-426.	1.1	50
229	Cognitive and neuropsychiatric effects of subthalamotomy for Parkinsonâ€™s disease. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 535-539.	1.1	32
230	Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. <i>Neurology</i> , 2009, 73, 1469-1477.	1.5	136
231	Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. <i>Lancet Neurology</i> , The, 2009, 8, 1150-1157.	4.9	734
232	Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. <i>Lancet Neurology</i> , The, 2009, 8, 1128-1139.	4.9	700
233	Reply: Corticobasal syndrome with Alzheimer's disease pathology. <i>Movement Disorders</i> , 2009, 24, 153-153.	2.2	0
234	Genomewide association study for susceptibility genes contributing to familial Parkinson disease. <i>Human Genetics</i> , 2009, 124, 593-605.	1.8	410

#	ARTICLE	IF	CITATIONS
235	Genomewide association study for onset age in Parkinson disease. <i>BMC Medical Genetics</i> , 2009, 10, 98.	2.1	104
236	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. <i>European Journal of Neurology</i> , 2009, 16, 297-309.	1.7	170
237	Parkinson's Disease: An Overview of Pathogenesis. , 2009, , 159-178.		0
238	Replication of association between ELAVL4 and Parkinson disease: the GenePD study. <i>Human Genetics</i> , 2008, 124, 95-99.	1.8	34
239	Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study. <i>Movement Disorders</i> , 2008, 23, 1596-1601.	2.2	8
240	Adenosine A _{2A} receptor antagonist istradefylline (KW6002) reduces off-time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US005). <i>Annals of Neurology</i> , 2008, 63, 295-302.	2.8	333
241	The Gly219Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. <i>BMC Medicine</i> , 2008, 6, 32.	2.3	102
242	Clinical symptoms in Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 207-216.	1.0	27
243	Neuropathology of Pick body disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 415-430.	1.0	12
244	The Epidemiology of vascular dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 639-658.	1.0	18
245	Biology and Neuropathology of Dementia in Syphilis and Lyme Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 825-844.	1.0	34
246	Perspectives of Alzheimer's disease treatments. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 273-290.	1.0	2
247	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 671-686.	1.0	12
248	Clinical aspects and biology of normal pressure hydrocephalus. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 887-902.	1.0	11
249	The Neuropathology of Vascular and Mixed Dementia and Vascular Cognitive Impairment. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 687-703.	1.0	6
250	Clinical aspects of Parkinson dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 303-306.	1.0	1
251	Current and future therapeutic approaches in progressive supranuclear palsy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 493-508.	1.0	6
252	Clinical and Therapeutic Aspects of Dementia in Syphilis and Lyme Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 819-823.	1.0	5

#	ARTICLE	IF	CITATIONS
253	Haplotypes and gene expression implicate the <i>MAPT</i> region for Parkinson disease. <i>Neurology</i> , 2008, 71, 28-34.	1.5	103
254	History of Dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 3-13.	1.0	6
255	Quality of Life in Dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 97-100.	1.0	4
256	Neuropathology and genetics of corticobasal degeneration. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 523-532.	1.0	2
257	Neuropathology of Hereditary Forms of Frontotemporal Dementia and Parkinsonism. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 393-414.	1.0	10
258	Preface. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, ix.	1.0	0
259	Progressive supranuclear palsy and corticobasal degeneration: similarities and differences. <i>Future Neurology</i> , 2008, 3, 299-307.	0.9	0
260	Is it PD, PSP, CBD, DLB, or MSA?. , 2008, , 219-222.		0
261	Update of atypical parkinsonian disorders. <i>Current Opinion in Neurology</i> , 2007, 20, 434-437.	1.8	8
262	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 251-257.	0.9	104
263	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 329-336.	0.9	41
264	Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms. <i>American Journal of Human Genetics</i> , 2007, 80, 769-778.	2.6	68
265	Unraveling progressive supranuclear palsy: from the bedsideback to the bench. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S341-S346.	1.1	22
266	Neurobiology of Progressive Supranuclear Palsy. , 2007, , 105-110.		1
267	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	2.2	2,497
268	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324.	2.2	885
269	Current and future treatments in progressive supranuclear palsy. <i>Current Treatment Options in Neurology</i> , 2006, 8, 211-223.	0.7	19
270	Alzheimer's disease presenting as corticobasal syndrome. <i>Movement Disorders</i> , 2006, 21, 2018-2022.	2.2	62

#	ARTICLE	IF	CITATIONS
271	Lrrk2 and Lewy body disease. <i>Annals of Neurology</i> , 2006, 59, 388-393.	2.8	259
272	Influence of Heterozygosity for Parkin Mutation on Onset Age in Familial Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 826.	4.9	147
273	Measuring quality of life in PSP: The PSP-QoL. <i>Neurology</i> , 2006, 67, 39-44.	1.5	61
274	Penguins and hummingbirds: Midbrain atrophy in progressive supranuclear palsy. <i>Neurology</i> , 2006, 66, 949-950.	1.5	74
275	Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD Study. <i>Neurology</i> , 2006, 67, 2206-2210.	1.5	38
276	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. <i>Neurology</i> , 2005, 65, 1863-1872.	1.5	4,604
277	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. <i>Movement Disorders</i> , 2005, 20, 982-988.	2.2	111
278	"Applause sign" helps to discriminate PSP from FTD and PD. <i>Neurology</i> , 2005, 64, 2132-2133.	1.5	121
279	What is an Atypical Parkinsonian Disorder?. , 2005, , 1-9.		6
280	Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski's description of PSP 40 years ago and Albert's delineation of the subcortical dementia 30 years ago. <i>Neurocase</i> , 2005, 11, 250-262.	0.2	18
281	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 2005, 14, 3281-3292.	1.4	156
282	Bilateral subthalamotomy in Parkinson's disease: initial and long-term response. <i>Brain</i> , 2005, 128, 570-583.	3.7	184
283	BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. <i>Neurology</i> , 2005, 65, 1823-1825.	1.5	67
284	Progressive Supranuclear Palsy and Corticobasal Degeneration. , 2005, , 505-514.		1
285	Diagnostic issues in non-AD dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 363-374.	0.8	2
286	Update on progressive supranuclear palsy. <i>Current Neurology and Neuroscience Reports</i> , 2004, 4, 296-302.	2.0	38
287	Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. <i>NeuroImage</i> , 2004, 21, 714-724.	2.1	145
288	ATYPICAL PARKINSONIAN DISORDERS. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2004, 10, 42-64.	0.4	4

#	ARTICLE	IF	CITATIONS
289	Verifying Clinical Criteria for Parkinsonian Disorders with CART Decision Trees. Lecture Notes in Computer Science, 2004, , 1018-1024.	1.0	0
290	Update on epidemiological aspects of progressive supranuclear palsy. Movement Disorders, 2003, 18, 43-50.	2.2	121
291	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Annals of Neurology, 2003, 54, S15-S19.	2.8	496
292	Yes/no reversals as neurobehavioral sequela: a disorder of language, praxis, or inhibitory control?. European Journal of Neurology, 2003, 10, 103-106.	1.7	22
293	Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1215-1220.	0.9	199
294	Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology, 2003, 60, 917-922.	1.5	113
295	Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration. Journal of Neuropathology and Experimental Neurology, 2002, 61, 935-946.	0.9	592
296	Freezing of gait in postmortem-confirmed atypical parkinsonism. Movement Disorders, 2002, 17, 1041-1045.	2.2	46
297	Mitochondrial Dysfunction in Cybrid Lines Expressing Mitochondrial Genes from Patients with Progressive Supranuclear Palsy. Journal of Neurochemistry, 2002, 75, 1681-1684.	2.1	83
298	An open letter to the Committee on The Nobel Prize in Medicine. Parkinsonism and Related Disorders, 2001, 7, 149-155.	1.1	9
299	Therapy and management of frontal lobe dementia patients. Neurology, 2001, 56, S41-5.	1.5	36
300	Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2001, 13, 42-49.	0.9	149
301	Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease. European Journal of Neurology, 2001, 8, 707-710.	1.7	66
302	Impairment of eyeblink classical conditioning in progressive supranuclear palsy. Movement Disorders, 2001, 16, 240-251.	2.2	12
303	Neuropsychiatric assessment of Gilles de la Tourette patients: Comparative study with other hyperkinetic and hypokinetic movement disorders. Movement Disorders, 2001, 16, 1098-1104.	2.2	42
304	Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. BMC Neurology, 2001, 1, 3.	0.8	69
305	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology, 2001, 56, 1702-1706.	1.5	392
306	Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders. Archives of Neurology, 2001, 58, 259.	4.9	375

#	ARTICLE	IF	CITATIONS
307	Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy. <i>Neurology</i> , 2001, 57, 138-140.	1.5	37
308	Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. <i>Neurology</i> , 2001, 56, 957-963.	1.5	85
309	Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. <i>Neurology</i> , 2001, 57, 467-473.	1.5	160
310	Diagnosis and Management of Progressive Supranuclear Palsy. <i>Seminars in Neurology</i> , 2001, 21, 041-048.	0.5	60
311	Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 436-438.	2.2	30
312	Research goals in progressive supranuclear palsy. <i>Movement Disorders</i> , 2000, 15, 446-458.	2.2	29
313	Language disturbances in corticobasal degeneration. <i>Neurology</i> , 2000, 54, 990-992.	1.5	72
314	Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. <i>Neurology</i> , 2000, 54, 1029-1032.	1.5	146
315	The FAB. <i>Neurology</i> , 2000, 55, 1621-1626.	1.5	3,317
316	Pupillary diameter assessment: Need for a graded scale. <i>Neurology</i> , 2000, 54, 530-530.	1.5	48
317	Progression of Hoehn and Yahr stages in parkinsonian disorders: A clinicopathologic study. <i>Neurology</i> , 2000, 55, 888-891.	1.5	107
318	Evaluation of surgery for Parkinson's disease. <i>Neurology</i> , 1999, 53, 1910-1910.	1.5	115
319	Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 620-623.	0.9	171
320	Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy. <i>Human Molecular Genetics</i> , 1999, 8, 711-715.	1.4	749
321	Effects of Physostigmine on Swallowing and Oral Motor Functions in Patients with Progressive Supranuclear Palsy: A Pilot Study. <i>Dysphagia</i> , 1999, 14, 165-168.	1.0	35
322	Ideomotor apraxia in progressive supranuclear palsy: A case study. <i>Movement Disorders</i> , 1999, 14, 162-166.	2.2	11
323	Progression of falls in postmortem-confirmed Parkinsonian disorders. <i>Movement Disorders</i> , 1999, 14, 947-950.	2.2	144
324	Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. <i>Neurology</i> , 1999, 53, 1292-1292.	1.5	224

#	ARTICLE	IF	CITATIONS
325	Atypical parkinsonism in the French West Indies. <i>Lancet, The</i> , 1999, 354, 1472-1473.	6.3	1
326	Importance of deficits in executive functions. <i>Lancet, The</i> , 1999, 354, 1921-1923.	6.3	135
327	Clinicopathologic Case Report. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999, 11, 107-112.	0.9	0
328	Recent advances in atypical parkinsonian disorders. <i>Current Opinion in Neurology</i> , 1999, 12, 441-446.	1.8	36
329	A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration. <i>Neurology</i> , 1999, 52, 404-404.	1.5	13
330	Dysfunction of Ib (Autogenic) spinal inhibition in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 1998, 13, 668-672.	2.2	12
331	Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. <i>Journal of Neural Transmission</i> , 1998, 105, 217-227.	1.4	53
332	Consensus statement on the diagnosis of multiple system atrophy. <i>Clinical Autonomic Research</i> , 1998, 8, 359-362.	1.4	823
333	Limb shaking in multiple system atrophy. <i>European Journal of Neurology</i> , 1998, 5, 113-115.	1.7	0
334	Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. <i>European Journal of Neurology</i> , 1998, 5, 451-457.	1.7	36
335	Methodological and Research Issues in the Evaluation of Biological Diagnostic Markers for Alzheimer's Disease. <i>Neurobiology of Aging</i> , 1998, 19, 121-123.	1.5	7
336	Is EEG useful in the differential diagnosis of parkinsonism?. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 79-80.	1.1	5
337	Progressive supranuclear palsy. <i>Neurology</i> , 1998, 50, 1637-1647.	1.5	119
338	Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 64, 184-189.	0.9	288
339	Parkinsonian Features. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 1654.	3.8	19
340	Apathy Is Not Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1998, 10, 314-319.	0.9	554
341	Clinical and Genetic Aspects of Progressive Supranuclear Palsy. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 107-114.	1.2	30
342	Neuropsychiatric features of corticobasal degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 65, 717-721.	0.9	147

#	ARTICLE	IF	CITATIONS
343	Pharmacological Therapy in Progressive Supranuclear Palsy. Archives of Neurology, 1998, 55, 1099.	4.9	105
344	Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies. Archives of Neurology, 1998, 55, 969.	4.9	325
345	Progressive supranuclear gaze palsy is in linkage disequilibrium with the ϵ , and not the δ -synuclein gene. Neurology, 1998, 50, 270-273.	1.5	128
346	Neuropsychiatric Assessment of Patients With Hyperkinetic and Hypokinetic Movement Disorders. Archives of Neurology, 1998, 55, 1313.	4.9	128
347	Caregiving in progressive supranuclear palsy. Neurology, 1998, 51, 1303-1309.	1.5	31
348	Apolipoprotein Epsilon4 (Epsilon) Allele Does Not Affect the Onset or Symptom Severity in Progressive Supranuclear Palsy. Archives of Neurology, 1998, 55, 752-754.	4.9	10
349	Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology, 1997, 48, 1654-1662.	1.5	98
350	Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain, 1997, 120, 1541-1552.	3.7	132
351	What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?. Archives of Neurology, 1997, 54, 937.	4.9	222
352	The clinical and pathologic hallmarks of progressive supranuclear palsy. Current Opinion in Neurology, 1997, 10, 346-350.	1.8	20
353	What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology, 1997, 49, 62-69.	1.5	80
354	Accuracy of the Clinical Diagnosis of Corticobasal Degeneration. Neurology, 1997, 48, 119-125.	1.5	436
355	Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski) Tj ETQq1 1 0.784314 rgBT/Overlo	3.7	148
356	Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. Journal of Neural Transmission, 1997, 104, 845-865.	1.4	39
357	Visualizing Cortical Activation during Mental Calculation with Functional MRI. NeuroImage, 1996, 3, 97-103.	2.1	192
358	Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology, 1996, 47, 1-9.	1.5	2,510
359	Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology, 1996, 46, 922-930.	1.5	441
360	Neuropsychiatric aspects of progressive supranuclear palsy. Neurology, 1996, 47, 1184-1189.	1.5	237

#	ARTICLE	IF	CITATIONS
361	Preserved cognitive processes in cerebellar degeneration. Behavioural Brain Research, 1996, 79, 131-135.	1.2	44
362	641 Accuracy of the clinical diagnosis of pick's disease. Neurobiology of Aging, 1996, 17, S159-S160.	1.5	0
363	What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?. Brain, 1996, 119, 831-839.	3.7	11
364	Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders. Journal of Neuropathology and Experimental Neurology, 1996, 55, 97-105.	0.9	417
365	Progressive supranuclear palsy: a clinicopathological study of 21 cases. Acta Neuropathologica, 1996, 91, 427-431.	3.9	78
366	Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.. Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 615-620.	0.9	357
367	Can tropicamide eye drop response differentiate patients with progressive supranuclear palsy and Alzheimer's disease from healthy control subjects?. Neurology, 1996, 47, 1324-1326.	1.5	26
368	Reliability of the NINDS Myotatic Reflex Scale. Neurology, 1996, 47, 969-972.	1.5	83
369	A Reappraisal of Reliability and Validity Studies in Stroke. Stroke, 1996, 27, 2331-2336.	1.0	117
370	What can preservation of autobiographic memory after muscarinic blockade tell us about the scopolamine model of dementia?. Neurology, 1995, 45, 387-389.	1.5	8
371	Neuropsychological Features of Progressive Supranuclear Palsy. Brain and Cognition, 1995, 28, 311-320.	0.8	60
372	Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Annals of Neurology, 1994, 36, 55-61.	2.8	54
373	Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive) Tj ETQq1 1.0,784314 rgBT /O 1.5 808	1.5	808
374	Cerebellar cognition. Neurology, 1993, 43, 2153.	1.5	2
375	Cognitive planning deficit in patients with cerebellar atrophy. Neurology, 1992, 42, 1493-1493.	1.5	401
376	CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy. Acta Neurologica Scandinavica, 1992, 86, 204-206.	1.0	5
377	Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 25-29.	0.9	100
378	Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 832-835.	0.9	15

#	ARTICLE	IF	CITATIONS
379	Progressive supranuclear palsy. <i>Neurology</i> , 1991, 41, 1257-1257.	1.5	34
380	Selective Deficits in Alzheimer and Parkinsonian Dementia: Visuospatial Function. <i>Canadian Journal of Neurological Sciences</i> , 1990, 17, 292-297.	0.3	39
381	Implicit Learning in Patients with Alzheimer's Disease. <i>Pharmacopsychiatry</i> , 1990, 23, 94-101.	1.7	88
382	Frontal Lobe Function in Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 1990, 47, 553-558.	4.9	140
383	Selective deficits in cognition and memory in high-functioning parkinsonian patients.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990, 53, 603-606.	0.9	65
384	Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 1990, 47, 1346-1350.	4.9	37
385	Memory Impairment in Patients With Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 1989, 46, 765-767.	4.9	63
386	Physostigmine treatment of progressive supranuclear palsy. <i>Annals of Neurology</i> , 1989, 26, 404-407.	2.8	44
387	Unilateral left cerebral deterioration documented by CT, MRI, and neuropsychological studies: A possible case of pick's disease. <i>Developmental Neuropsychology</i> , 1988, 4, 295-302.	1.0	1
388	Slowed Information Processing in Multiple Sclerosis. <i>Archives of Neurology</i> , 1988, 45, 281-285.	4.9	213
389	Multiple Memory Deficits in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 1988, 45, 607.	4.9	155
390	Behcet's syndrome masquerading as tumor. <i>Neuroradiology</i> , 1987, 29, 103-103.	1.1	21
391	Does reversed laterality really exist in dextrals? A case study. <i>Neuropsychologia</i> , 1986, 24, 241-254.	0.7	19
392	Woman with gait impairment and difficulty reading. , 0, , 229-237.		0
393	Clinical Spectrum of Tauopathies. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	9